-
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Eur Heart J. 2006 Mar;27(5):589-95
PMID: 16431875
-
Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.
Clin Pharmacokinet. 2000 Dec;39(6):397-412
PMID: 11192473
-
Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition.
J Cardiovasc Pharmacol. 2001 Aug;38(2):325-34
PMID: 11483882
-
Pulmonary arterial hypertension: new insights and new hope.
Respirology. 2006 Jan;11(1):6-17
PMID: 16423196
-
Potential vascular benefits of statins.
Am J Med. 2005 Dec;118 Suppl 12A:62-7
PMID: 16356810
-
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
J Clin Invest. 2001 Nov;108(10):1429-37
PMID: 11714734
-
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
J Am Coll Cardiol. 2006 May 16;47(10 ):2049-56
PMID: 16697324
-
Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.
Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L668-76
PMID: 16698853
-
Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.
Pharmacol Res. 1997 Aug;36(2):115-21
PMID: 9344639
-
The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society.
J Atheroscler Thromb. 2005;12(6):338-42
PMID: 16394618
-
Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload.
Biochim Biophys Acta. 2002 Apr 24;1586(3):233-42
PMID: 11997075
-
The activation pattern of the antioxidant enzymes in the right ventricle of rat in response to pressure overload is of heart failure type.
Heart Dis. 2003 Sep-Oct;5(5):308-12
PMID: 14503927
-
Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
Cardiovasc Res. 2000 Sep;47(4):648-57
PMID: 10974215
-
Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats.
J Cardiovasc Pharmacol. 2005 Oct;46(4):452-8
PMID: 16160596
-
How valid are animal models to evaluate treatments for pulmonary hypertension?
Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):391-400
PMID: 16932922
-
[Pulmonary artery hypertension associated with connective tissue diseases].
Presse Med. 2003 May 17;32(17):789-99
PMID: 12856325
-
Direct vascular effects of HMG-CoA reductase inhibitors.
Trends Cardiovasc Med. 2000 May;10(4):143-8
PMID: 11239793
-
Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.
Nat Rev Drug Discov. 2005 Dec;4(12):977-87
PMID: 16341063
-
A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
Am Heart J. 2006 Apr;151(4):851.e1-5
PMID: 16569546
-
Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase.
Eur J Vasc Endovasc Surg. 2001 Apr;21(4):295-300
PMID: 11359328
-
Simvastatin treatment of pulmonary hypertension: an observational case series.
Chest. 2005 Apr;127(4):1446-52
PMID: 15821229
-
Statin mediated protection of the ischemic myocardium.
Vascul Pharmacol. 2005 Apr-May;42(5-6):265-70
PMID: 15922259
-
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):401-14
PMID: 16896805
-
Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.
Mol Pharmacol. 2001 Mar;59(3):646-54
PMID: 11179461
-
Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation.
Circ Res. 1996 Dec;79(6):1131-42
PMID: 8943951
-
[Collagen diseases with pulmonary hypertension].
Nihon Rinsho Meneki Gakkai Kaishi. 2004 Jun;27(3):127-36
PMID: 15291249
-
Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction.
Naunyn Schmiedebergs Arch Pharmacol. 2006 Jun;373(3):221-9
PMID: 16736159
-
Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
Arthritis Rheum. 2006 Jan;54(1):184-91
PMID: 16385514
-
Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
Curr Med Res Opin. 2005 Sep;21(9):1389-99
PMID: 16197657
-
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Circulation. 1998 Mar 31;97(12):1129-35
PMID: 9537338
-
Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.
Intern Med. 2006;45(2):51-5
PMID: 16484739
-
Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats.
Circulation. 2001 Aug 21;104(8):945-50
PMID: 11514384
-
Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.
Am J Respir Crit Care Med. 2002 Nov 15;166(10):1403-8
PMID: 12406854
-
Primary and secondary pulmonary hypertension in systemic lupus erythematosus.
Lupus. 2000;9(5):338-42
PMID: 10878725
-
Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.
Circulation. 2003 Sep 30;108(13):1640-5
PMID: 12963647
-
Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells.
Toxicol Appl Pharmacol. 1998 Aug;151(2):236-44
PMID: 9707500
-
Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
Atherosclerosis. 2000 Sep;152(1):217-27
PMID: 10996358
-
Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Am J Cardiol. 2005 Sep 5;96(5A):11F-23F
PMID: 16126019
-
Attenuation of chronic hypoxic pulmonary hypertension by simvastatin.
Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H938-45
PMID: 12750068
-
Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost.
Rheumatol Int. 2006 Jan;26(3):264-9
PMID: 16010558
-
Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow.
Heart Vessels. 2006 May;21(3):169-79
PMID: 16715192
-
Rac1 disrupts p67phox/p40phox binding: a novel role for Rac in NADPH oxidase activation.
Biochem Biophys Res Commun. 1999 Sep 16;263(1):118-22
PMID: 10486263
-
Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
Atherosclerosis. 2003 Jul;169(1):19-29
PMID: 12860247
-
Statin-stimulated nitric oxide release from endothelium.
Med Sci Monit. 2001 Jul-Aug;7(4):622-7
PMID: 11433186
-
Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal.
Am J Cardiol. 2006 Apr 1;97(7):1002-6
PMID: 16563905
-
All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells.
Atherosclerosis. 2003 Oct;170(2):237-43
PMID: 14612203
-
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Am Heart J. 2006 Feb;151(2):273-81
PMID: 16442888
-
Not all statins interfere with clopidogrel during antiplatelet therapy.
Eur J Clin Invest. 2005 Aug;35(8):476-81
PMID: 16101667
-
Statins as anti-inflammatory agents.
Trends Pharmacol Sci. 2002 Oct;23(10):482-6
PMID: 12368073
-
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Am J Cardiovasc Drugs. 2001;1(6):411-20
PMID: 14728000
-
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
Biochem Pharmacol. 2004 Jun 15;67(12):2175-86
PMID: 15163549
-
A factor preventing the major head protein of bacteriophage T4 from random aggregation.
J Mol Biol. 1970 Jan 14;47(1):69-85
PMID: 5413343